CD274 and non-small cell lung carcinoma: In addition, we describe the identification and validation of scoring criteria (defined with tissues from a durvalumab clinical trial) that can be used to classify samples as PD-L1 high expression or PD-L1 low/no expression in NSCLC and HNSCC tissue.